secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001613103-25-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q3 FY2025 revenue $8.3B, EPS $1.39 non-GAAP beat; organic growth 4.1%
-------------------------------------------------------------------------------

- Revenue $8.292B (+2.5% reported, +4.1% organic); GAAP EPS $1.01 (+2%), non-GAAP EPS $1.39 (+7%, above guidance).
- Cardiovascular up 5% organic led by PFA (low-20s growth) and Micra (mid-20s growth); Diabetes up 10.4% organic.
- Neuroscience up 5.2% organic (Neuromodulation low-double digit); Medical Surgical down 0.4% organic.
- FY25 guidance reaffirmed: organic rev growth 4.75%-5%, non-GAAP EPS $5.44-$5.50.
- CMS opened NCA for Renal Denervation; FDA approved additional PFA manufacturing site in Galway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310325000019/0001613103-25-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310325000019/mdt-20250218.htm
  HTML page:      https://secwatch.observer/filing/0001613103-25-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer